Related by context. All words. (Click for frequent words.) 76 endogenous interferons 68 non nucleoside inhibitor 66 oral prodrug 66 HCV RNA polymerase 66 small molecule inducer 65 oral picoplatin 65 novel VDA molecule 64 TLR7 pathway 64 Presents Preclinical Data 64 orally administered inhibitor 64 TLR7 agonist 64 Reports Preclinical Data 63 oral nucleoside analogue 63 Begins Dosing 63 Initiates Phase II 63 Submits Biologics License Application 63 GVAX ® 63 Hsp# Inhibitor 63 novel histone deacetylase 63 Initiates Phase III 63 telomerase therapeutic 63 agonistic human 63 demonstrated antitumor activity 63 peptidic compound 63 agonists antagonists 63 JAK2 Inhibitor 62 AKT inhibitor 62 ADP receptor antagonist 62 agonist compounds 62 Phase 2b Clinical Trial 62 Completes Patient Enrollment 62 Initiates Phase 62 TLR9 agonist 62 highly selective inhibitor 62 Presents Preclinical 62 mertansine 62 includes TOLAMBA TM 61 PRN FDA Approves 61 AAG geldanamycin analog 61 Receptor Antagonist 61 factor TNF receptor 61 novel tubulin binding 61 2 inhibitor CYT# 61 HCD# [002] 61 SPRYCEL ® 61 novel therapeutic antibodies 61 Initiates Enrollment 61 TNF alpha selectively neutralizing 61 adecatumumab MT# 61 pathophysiological effects 61 beta 1a 61 Initiates Clinical 61 developing Zerenex ferric 61 dasatinib Sprycel ® 61 CYT# potent vascular disrupting 61 Xcytrin R 61 small molecule Hedgehog 61 nucleoside analog 61 Omacetaxine 61 TransVax ™ 61 Kinase Inhibitor 61 Pruvel TM 61 cisplatin gemcitabine 61 hypereosinophilic syndrome 60 lintuzumab SGN 60 Successfully Completes Phase 60 Meets Primary Endpoint 60 DNA methyltransferase inhibitors 60 Pathway Inhibitor 60 PNP inhibitor 60 PI3K/Akt pathway inhibitor 60 Panzem R 60 soluble tumor necrosis 60 XL# anticancer compounds 60 Merck OSI Pharmaceuticals 60 platform HDL Mimetic 60 Antibody Drug Conjugate 60 evaluating tivozanib 60 Receives Orphan Drug Designation 60 NS5B polymerase 60 OMP #R# 60 HQK 60 pan histone deacetylase 60 dextromethorphan quinidine 60 HGS ETR2 60 virus HCV protease inhibitor 60 oral proteasome inhibitor 60 Submits IND 60 receptor TLR 60 novel emulsion formulation 60 Factor Receptor 59 HCV protease 59 oncolytic virus therapies 59 pralatrexate injection folate analogue 59 Aflibercept 59 plus prednisone prednisolone 59 Receives Milestone Payment 59 ALN VSP Phase 59 dimebon latrepirdine 59 CD4 monoclonal antibody 59 investigational oral inhibitor 59 Initiate Phase 59 acyclovir Lauriad R 59 alpha folate receptor 59 NS5b 59 tramiprosate Alzhemed TM 59 targeting CD# 59 Peginterferon alfa 2b 59 ® lenalidomide 59 topoisomerase II inhibitor 59 Virulizin ® 59 ENMD # 59 nucleotide analog 59 Tyrosine Kinase Inhibitor 59 PEGylated Fab fragment 59 Panzem R NCD 59 MKC# MT 59 selective kinase inhibitor 59 Orally administered 59 IMiDs ® 59 IgG1 monoclonal antibody 59 mda 7 59 apoptosis inducer 59 HGS ETR1 mapatumumab 59 histone deacetylase inhibitor 59 R sorafenib tablets 59 Darinaparsin 59 Aurora Kinase 59 CDK cyclin dependent 59 liposomal formulation 59 ALN PCS 59 sapacitabine CYC# 59 XP# XP# 59 nilotinib Tasigna ® 59 anti secretory 59 Inc. Nasdaq MITI 59 Factor VIIa 59 Telik logo TELINTRA 58 oral anti arrhythmic 58 midstage clinical 58 NU# direct 58 class mGluR5 inhibitor 58 XL# XL# XL# XL# 58 potent cytotoxic 58 TO AVOID PREGNANCY WHILE 58 non nucleoside HCV 58 DEB# 58 Pruvel ™ 58 CD# CEA 58 Files IND 58 5 HT2A serotonin 58 PDE4 58 candidate deforolimus 58 small molecule tyrosine 58 oral dihydropyrimidine dehydrogenase DPD 58 Tumour Vascular Disrupting Agent 58 Bezielle 58 MEK inhibitor 58 R#/MEM # 58 Initiates Clinical Trial 58 Tarceva TM 58 Maxy G# 58 TRIOLEX HE# APOPTONE HE# 58 mGluR5 NAM 58 cortisol synthesis 58 Aurora kinase inhibitor 58 NPC 1C 58 estramustine 58 hyaluronidase enzyme 58 docetaxel Taxotere R 58 Lenocta TM sodium stibogluconate 58 ProMune 58 IMC #B 58 irinotecan doxorubicin oxaliplatin paclitaxel 58 #HT# 58 inflammatory PDE 58 vinorelbine tartrate 58 IMPDH inhibitor 58 THR beta agonist 58 Ceflatonin R 58 JAK1 58 potent triglyceride lowering 58 oral JAK1 58 albiglutide 58 urocortin 2 58 erlotinib Tarceva ® 58 Budesonide foam crofelemer 58 orally inhaled migraine 58 Receptor TLR 58 PEG SN# 58 Annamycin 58 selective serotonin 2C receptor 58 triggers apoptosis programmed 58 Archexin 58 Thiovir 58 thalidomide Thalomid 58 personalized dendritic 58 investigational humanized monoclonal antibody 58 paclitaxel Taxol ® 58 MT#/MEDI-# 58 TLR9 agonist IMO 58 folate analogue metabolic 58 5 FU leucovorin 58 HCV polymerase 58 Like Receptor 58 mitotic kinesin 58 HCV protease inhibitors 58 PRTX 58 Recombinant Human 57 GVAX R 57 generation purine nucleoside 57 potently inhibit 57 VEGFR2 inhibitor 57 MKC# 57 R lenalidomide 57 Aplidin R 57 Exherin 57 reversible inhibitor 57 Initiates Phase 2b 57 kidney urologic 57 Immunotherapeutic 57 Commences Phase 57 Present Preclinical Data 57 small molecule thrombopoietin 57 ELND-#/AZD-# 57 selective A2A adenosine receptor 57 apricitabine ATC 57 Preclinical studies suggest 57 selective modulator 57 Solazed TM 57 lead molecular radiotherapeutic 57 2 methoxyestradiol 57 oxidative stress inducer 57 CRTH2 57 Achieves Primary Endpoint 57 highly selective endothelin 57 polymerase inhibitor 57 Protease Inhibitor 57 PDE4 inhibitor 57 nilotinib Tasigna 57 Albuferon albinterferon alfa 2b 57 triciribine phosphate monohydrate 57 MET VEGFR2 57 Talactoferrin 57 weekly subcutaneous injections 57 Tesmilifene 57 Submits NDA 57 Receptor Antagonists 57 FUSILEV enhances 57 plus COPEGUS 57 cytokine refractory 57 Enzastaurin 57 visilizumab 57 Drug Candidate 57 Forodesine HCl 57 YONDELIS 57 selective inverse agonist 57 aurora kinase 57 osteolytic bone disease 57 volociximab 57 pemetrexed Alimta 57 Omacetaxine mepesuccinate 57 Kosan dependence 57 TKB# 57 ® bortezomib 57 aplindore 57 accumulate preferentially 57 molecular therapeutics immunotherapies 57 therapeutic monoclonal antibody 57 Talabostat 57 Receives Approvable Letter 57 ALTROPANE R 57 molecular imaging radiopharmaceutical 57 mGluR2 NAM 57 Ecallantide 57 XL# inhibits 57 CG# [003] 57 Therapeutic Competitors Companies 57 CYP#A# CYP#D# 57 Zalypsis 57 anti botulism antibody 57 LymphoStat B belimumab 57 certain protein tyrosine 57 targeted antifolate 57 immunomodulating 57 orally bioavailable 57 highly purified pasteurized 57 immune modulatory 57 immune stimulatory 57 inhibitor COX 57 Certolizumab 57 evaluating satraplatin 57 5 fluorouracil leucovorin 57 intranasal formulation 57 TLR7 56 potent suppressor 56 Romidepsin 56 selectively inhibited 56 continuous intravenous infusion 56 candidate REP# 56 non porcine pancreatic 56 metaglidasen 56 pan HDAC inhibitor 56 Panzem NCD 56 alvespimycin 56 DiLA2 liposomes 56 HepeX B TM 56 PDX pralatrexate 56 activin receptor type 56 candidates Azedra TM 56 TLR9 agonists 56 MCSP respectively 56 Long acting beta2 56 KNS # 56 Pazopanib 56 HDAC Inhibitor 56 anti atherothrombotic 56 adenosine A2A 56 please visit http:/www.vandapharma.com 56 5 HT2C 56 recurrent glioblastoma multiforme 56 commercialize CorMedix drug 56 Pharma Merck Serono 56 humanized anti 56 oral methylnaltrexone 56 CIMZIA TM 56 receptor partial agonist 56 potent antiproliferative 56 initiated Phase Ib 56 infectious diseases autoimmune diseases 56 Seliciclib 56 KSP inhibitor 56 TRO# 56 COPEGUS R 56 PEGylated interferon 56 IAP inhibitor 56 peptibody 56 pegylated interferon alfa 2a 56 delta opioid receptor 56 vascular disrupting agent 56 5 HT6 receptor 56 mitogen activated ERK kinase 56 systemically administered 56 ISTODAX 56 compound INCB# 56 Vidaza ® 56 immune modulator 56 anti CD3 monoclonal 56 Phase 2a Clinical Trial 56 GSK '# 56 SinuNase ™ 56 taxane resistant 56 vaccine RiVax TM 56 AGS PSCA 56 cathepsin K inhibitor 56 octreotide acetate 56 imatinib Gleevec ® 56 potently inhibited 56 HCV protease inhibitor 56 myelodysplastic myeloproliferative diseases 56 MTP inhibitor 56 anti miRs antisense oligonucleotide 56 targeted radiotherapeutic 56 apoptosis proteins 56 catheter occlusion 56 inhibit oxidative stress 56 humanized interleukin 6 56 IMiDs R 56 R roscovitine 56 Evoltra ® 56 Antigen Specific 56 sunitinib Sutent ® 56 CYC# 56 Files Investigational 56 JAK2 inhibitor 56 Aganocide ® 56 peripherally acting 56 Golimumab 56 receptor inhibitor 56 Investigational Treatment 56 partial agonist 56 humanized therapeutic 56 gastro intestinal inflammation 56 HGS ETR1 56 PrevOnco ™ 56 Coadministration 56 multi kinase inhibitor 56 HCV polymerase inhibitors 56 Aganocide 55 Luteinizing Hormone Releasing Hormone 55 selective inhibition 55 small molecule glucokinase 55 serotonin norepinephrine reuptake inhibitor 55 signal transduction inhibitor 55 cyclin dependent kinase inhibitor 55 attach auristatin 55 anti CTLA 55 receptor tyrosine kinase inhibitor 55 ispinesib SB # 55 selective antagonist 55 poly ADP ribose polymerase 55 DP VPA 55 semi synthetic lipoglycopeptide 55 8mg/kg 55 ritonavir boosted 55 Posiphen 55 cetuximab Erbitux R 55 targets Galectin receptors 55 oral Janus kinase 55 elotuzumab 55 Squalamine 55 Janus kinase 55 ChronVac C R 55 Xanafide 55 PKC# 55 Antitumor Activity 55 TELINTRA R 55 Maribavir 55 dopamine D2 55 EGFR HER2 55 selective estrogen receptor modulator 55 ganetespib 55 protein tyrosine phosphatase 1B 55 generation nucleoside analog 55 secretory phospholipase A2 55 Voreloxin 55 Pharmacokinetics PK 55 TREANDA 55 2A receptor agonist 55 humanized monoclonal 55 Daclizumab 55 TNF Tumor Necrosis Factor 55 proteasome inhibitor 55 topical antifungal product 55 Tumor Necrosis Factor 55 anti amnesic 55 novel immunotherapies 55 PLK1 SNALP 55 thiazolides 55 effector function 55 tumor vascular disrupting 55 PEG irinotecan 55 mg/m2 administered 55 Sudhir Agrawal D.Phil 55 investigational protease inhibitor 55 SAR# [002] 55 maximally tolerated lipid lowering 55 anthracycline taxane 55 PF # [002] 55 Phase 1b Clinical Trial 55 administered subcutaneously 55 serious cardiovascular thrombotic 55 palonosetron hydrochloride Injection Dacogen 55 CB2 selective receptor agonist 55 oral Factor Xa 55 chimeric monoclonal antibody 55 M# rationally 55 antibody MT# 55 HER1 55 Abrupt discontinuation 55 RNA antagonists 55 polysaccharide polymer 55 panitumumab Vectibix 55 Delta opioid receptor 55 OncoVEX GM CSF 55 anionic backbone 55 Atripla combines 55 BZL# 55 selective agonist 55 HIV treatments Reyataz 55 motexafin gadolinium Injection 55 alpha#beta# 55 Novel Oral 55 HSP# inhibitor 55 5 HT2A inverse 55 Angiotensin Converting Enzyme 55 EZN 55 XOMA 3AB 55 ASONEP 55 novel peptide 55 Granulocyte Colony Stimulating Factor 55 Fludara ® 55 Epothilones 55 LEP ETU 55 Emtriva Viread 54 nicotinic alpha 7 54 immunomodulatory 54 alpha 2a 54 ddRNAi 54 Belimumab 54 docetaxel Taxotere ® 54 bortezomib Velcade 54 Nasdaq IDRA today 54 PEGylated interferon beta 1a 54 oral immunomodulatory 54 VentiRx Pharmaceuticals 54 Pharmacodynamic 54 MGd 54 uric acid lowering 54 Vaxfectin 54 D aspartate NMDA receptor 54 Blinatumomab 54 lead compound ISA# 54 Systemic Delivery 54 amprenavir 54 receptor agonist 54 humanized monoclonal antibody 54 MSCRAMM ® 54 novel orally administered 54 Cytotoxic 54 IMA# 54 severe hypersensitivity reactions 54 PDE# 54 5 HT1A receptor 54 IG HCR ;) CO 54 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 54 torezolid phosphate 54 Ophena TM 54 MT# MEDI 54 TransVax tm 54 GW# [003] 54 MKC# MKC# PP 54 Pegasys ® 54 Cotara ® 54 oral antiviral 54 Chemophase 54 polyglutamate 54 receptor modulators 54 selective orally bioavailable 54 receptor agonists 54 Tibotec Therapeutics division 54 Vidaza R 54 nonhematologic adverse reactions 54 selective immunoproteasome inhibitor 54 Saxagliptin 54 Elesclomol 54 methyl D aspartate 54 Randomized Phase 54 Aliskiren 54 HuLuc# 54 5 HT6 54 Trastuzumab DM1 54 Vascular Endothelial Growth 54 Homspera TM 54 Darinaparsin Zinapar TM 54 irreversible inhibitor 54 Pivotal Phase 54 KRAS mutant 54 CORLUX CORT # 54 Tß4 54 Protein Kinase C 54 Akt inhibitor 54 RhuDex ® 54 vascular disrupting agents 54 xenograft models 54 IMC A# 54 Valortim R 54 3TC lamivudine 54 Gleevec resistant 54 Submits Supplemental 54 Alfacell proprietary ribonuclease 54 B lymphocyte stimulator 54 PEGylated anti 54 bevacizumab Avastin ® 54 IMiD 54 polymerase inhibitors 54 IAP inhibitors 54 commercializing oxidized glutathione 54 Prodrug 54 orally dosed 54 Fc fusion protein 54 PCK# 54 rxRNA 54 brivanib 54 Decitabine 54 biased ligand 54 lenalidomide Revlimid R 54 Ep CAM 54 radiation sensitizer 54 Plicera 54 tezampanel NGX# 54 psoriasis rheumatoid arthritis 54 hepatitis C lupus 53 Monoclonal Antibody 53 cetuximab Erbitux ® 53 vidofludimus 53 cyclophosphamide methotrexate 53 gonadotrophin releasing hormone GnRH 53 Clevudine 53 tiapamil 53 riociguat 53 including eniluracil ADH 53 VaxInnate proprietary 53 Gemzar ® 53 Intravenous CP 53 gastrin analogue TT 53 Nasulin ™ 53 Y2 receptor 53 systemic juvenile idiopathic 53 alpha TNFa 53 PDGFR B 53 Anticancer Compound 53 Muraglitazar 53 Multimeric 53 triggers apoptosis 53 TLR8 agonists 53 oncolytic 53 Prulifloxacin 53 drug conjugate 53 AFREZZA TM 53 sodium glucose cotransporter 53 forodesine hydrochloride 53 Actilon 53 epigenetic therapies 53 VP# [004] 53 Pruvel 53 OMP #M# 53 peripherally restricted 53 OncoVex 53 Cathepsin S 53 AMPK activators 53 Teriflunomide 53 Aztreonam lysine 53 EnVivo Pharmaceuticals Inc. 53 Onconase 53 HyperAcute 53 demethylating agent 53 CCR5 antagonist 53 #D#C# 53 histone deacetylase HDAC inhibitor 53 inverse agonist 53 Janus Kinase 53 KRN# 53 Tumor necrosis factor 53 AdVac ® 53 Zoraxel 53 cyclin dependent kinase CDK 53 ACTEMRA TM 53 Small Modular SMIP 53 thrombopoietin TPO 53 PANVAC VF 53 TLR3 agonist 53 epothilones 53 Rigel R# 53 myopathy rhabdomyolysis 53 Aclidinium 53 STEDESA 53 Laquinimod 53 alpha#beta# integrin 53 milatuzumab 53 induces apoptosis 53 Belinostat 53 sodium stibogluconate 53 Quinamed R 53 Inhalation Powder 53 Cariprazine 53 nicotinic 53 potent anticancer 53 protein rFIXFc 53 DepoVax TM 53 XOMA 3AB biodefense 53 Small Molecule 53 plus fludarabine 53 Sphingosine 1 53 transcriptase inhibitor NNRTI 53 Methylnaltrexone 53 HER pathway 53 JAK inhibitors 53 Elacytarabine 53 Monopril 53 Topotecan 53 pyrimidine nucleoside analog 53 receptor blocker 53 Vectical 53 kinesin spindle protein KSP 53 A3 adenosine receptor 53 introduced NEUGENE 53 Capesaris 53 anti EGFR antibody 53 valtorcitabine 53 PEG Interferon lambda 53 receptor inhibiting monoclonal 53 Traficet EN 53 specifically hypoactive sexual 53 patients coinfected 53 decompensated liver disease 53 Cethromycin 53 Thiarabine 53 thrombin receptor 53 dopamine receptor agonist 53 Like Receptor TLR 53 Dose Escalation 53 talactoferrin 53 BYETTA exenatide injection 53 Adenosine A2A 53 Tolvaptan 53 RAV# 53 proprietary BiTE ® 53 Histone Deacetylase 53 TLR9 53 fusion enhancers 53 AEG# 53 FGFR 53 #-#-#-# s.archambault @ evolutiongrp.com 53 Cancidas 53 therapeutically inactive prodrug 53 Vilazodone 53 5 HT4 53 TÎ ² 4 53 TNF á 53 Vidofludimus 53 Known hypersensitivity 53 interleukin IL -# 53 selective adenosine 53 saquinavir ritonavir 53 selective inhibitor 53 investigational compounds 53 headache nasopharyngitis 53 PSN# [001] 52 PENNVAX B 52 OXi# 52 AVN# [001] 52 erythropoiesis stimulating agent 52 Epidermal Growth Factor Receptor 52 isoform selective 52 doxorubicin cyclophosphamide 52 compound perifosine 52 sodium glucose transporter 52 antimitotic 52 Ad5FGF 4 52 RAS MAPK pathway 52 tyrosine kinase inhibitor 52 ISIS # 52 Biogen Genentech 52 cytochrome P 52 colesevelam HCl 52 ascending dose 52 FOLFOX chemotherapy 52 ™ pralatrexate injection 52 Inotek Pharmaceuticals Corporation 52 highly selective adenosine 52 JAK inhibitor 52 maximally tolerated dose 52 Temsirolimus 52 mGluR5 antagonists 52 Lung Cancer Drug 52 immuno inflammatory diseases 52 sulfonylhydrazine class 52 subcutaneously administered 52 4mg/kg 52 Fast Track designations 52 muscarinic 52 RTP #i 52 cytotoxic T lymphocyte 52 Rindopepimut 52 Pimavanserin 52 lenalidomide dexamethasone 52 peginterferon alfa 52 CB2 receptor selective 52 replicon 52 metastatic colorectal 52 Nasdaq MITI biopharmaceutical 52 related apoptosis inducing 52 Degarelix 52 TAFA# 52 R bortezomib 52 BRAF kinase 52 diabetic neuropathic pain 52 products MKC# PP 52 #mg BID [003] 52 seliciclib CYC# 52 refractory acute myeloid 52 Adjuvanted 52 AVE# 52 neuropathic pain spasticity 52 HuMax CD4 52 EDEMA3 trial 52 Plasmid DNA 52 immunostimulatory 52 directed radiotherapeutic antibody 52 Nanobody R 52 histone deacetylase HDAC 52 either acutely decompensated 52 Perifosine 52 prostaglandin D2 52 ritonavir boosted protease inhibitor 52 nonclinical studies 52 R adalimumab 52 limiting toxicity DLT 52 drug conjugates ADCs 52 IIB ActRIIB 52 Sodium oxybate 52 Adenosine Therapeutics 52 GSK# [001] 52 azoles 52 CINQUIL 52 albumin naturally occurring 52 Tesetaxel 52 Micromet proprietary BiTE 52 briakinumab 52 histone deacetylase 52 endothelin receptor antagonists 52 SynCon ™ DNA 52 commercialized DURECT 52 CYT# vascular disrupting 52 Nasdaq IDRA 52 SGLT 52 EMSAM 52 Aptamer 52 sorafenib Nexavar 52 enhance ApoA 52 advanced metastatic renal 52 RAF kinase VEGFR 52 NEUGENE antisense 52 hypoxia selective 52 plus methotrexate 52 Enhanze TM Technology 52 doxorubicin Adriamycin 52 cyclooxygenase COX 52 Ixabepilone 52 interferon alfa 2b 52 Gefitinib 52 potent inducer 52 humanized antibody 52 Paliperidone Palmitate 51 adriamycin 51 dipeptidyl peptidase IV 51 neurokinin 1 51 Pemetrexed 51 penetrating peptides 51 Arranon 51 deforolimus 51 agonist 51 neuronal nicotinic receptor NNR 51 TBC M4 51 peroxisome proliferator activated 51 HERCEPTIN 51 Steve Worland Ph.D. 51 CTA# Injection 51 soluble TNF receptor 51 cannabinor 51 Pharmacokinetics 51 Sphingomab TM 51 cyclophilin inhibitors 51 INVANZ 51 pleconaril 51 sphingosine 1 51 Pagoclone 51 guanfacine extended release 51 using VIAdel TM 51 CIMZIA ™ 51 mapatumumab 51 Zoraxel TM 51 Genotyping Test 51 microtubule inhibitor 51 Anidulafungin 51 somatostatin 51 Linagliptin 51 includes ecallantide recombinant 51 Nanobody 51 anthracycline derivative 51 PI3K inhibitor 51 reversible inhibitors 51 pegylated 51 SNALP technology 51 administered concomitantly 51 cardiotoxic 51 targets HGF FGFR 51 5 HT2A 51 cMet 51 PI3 Kinase 51 CA4P 51 potent inhibitor 51 JZP 51 melphalan prednisone 51 serologically active systemic lupus 51 intranasal formulations 51 LPA1 51 intranasal insulin 51 NK1 51 telomerase reverse transcriptase 51 interferon lambda 51 motesanib 51 refractory NSCLC 51 TTF Therapy 51 CIMZIA R 51 Vildagliptin 51 taxane refractory 51 anti leukemic 51 anticancer therapeutics 51 Lixisenatide 51 CDDO Im 51 systemic immunosuppressive 51 5 HT2A receptor 51 Angiocept 51 MDS MPD 51 Perforomist ™ Inhalation Solution 51 negative allosteric modulator 51 tezampanel 51 microsomal triglyceride transfer 51 oral rivaroxaban 51 taxane derivative 51 selectively binds 51 acting fibrinolytic 51 naïve HCV 51 Liposomal 51 immunotoxin 51 Imatinib mesylate 51 #HT#A 51 targeted nucleotide prodrug 51 therapeutic peptide Thymosin 51 PSN# [002] 51 causes myocardial ischemic 51 Sphingomab 51 TLR agonists 51 AFREZZA ™ 51 antineoplastic 51 protein kinase inhibitors 51 danoprevir 51 PrevOnco 51 Upregulation 51 nucleoside analogues 51 Linaclotide 51 E#F# 51 Proquin XR 51 QRX 51 Tofacitinib 51 include Altastaph TM 51 Eculizumab 51 ularitide 51 eltrombopag 51 H2 antagonists 51 Locked Nucleic Acid 51 ELADUR 51 doxepin HCl 51 selective phosphodiesterase 51 Receptor Agonist 51 Interferon alfa 51 Ganciclovir 51 inecalcitol 51 anthracycline containing 51 nicotinic acetylcholine receptor 50 vesicular monoamine transporter 50 favorable pharmacokinetic profile 50 epoetin zeta 50 5 HT4 receptor 50 XOMA proprietary 50 Darapladib 50 Unit Dose Budesonide 50 Allovectin 7 ® 50 sapropterin dihydrochloride Phase 50 DiLA2 50 Oral NKTR 50 Parkinson disease levodopa induced 50 Prosaptide 50 FLT3 50 alkylating 50 GPR# agonist 50 Flt3 50 RON Notch 50 proguanil 50 neuropathic pain metabolic diseases 50 HMG CoA reductase inhibitors 50 defensin mimetic antibiotic 50 Itraconazole 50 Irinotecan 50 RAPAMUNE 50 myasthenia gravis Huntington 50 Gammagard Liquid 50 Navelbine ® 50 achieve sustained virologic 50 anticancer activity 50 placebo intravenously 50 HSP# inhibitors 50 using Crucell PER.C6 50 kinase PI3K 50 hepatic insufficiency 50 myelofibrosis polycythemia vera 50 TLR8 50 Pertuzumab 50 IGF1R 50 administered intranasally 50 chemokine receptor 50 Eszopiclone 50 danazol 50 highly immunogenic 50 dependent cellular cytotoxicity 50 abacavir lamivudine 50 phosphatidylinositol 3 50 DGAT 50 Pancreate 50 trivalent seasonal influenza VLP 50 AFREZZA ® 50 Juvaris BioTherapeutics 50 aripiprazole Abilify 50 delta isoform 50 infectious diseases autoimmune 50 TLR9 mediated immune 50 imatinib resistant